JAK2 V617 Mutation Test, With Reflex To Jak2 Ex- 12, CALR Ex-9 Mutation And MPL W515, S505 Mutation, Bone Marrow in Vizag
50+ booked in last 3 daysOverview
JAK2 V617 Mutation, with reflex to Jak2 Ex-12, CALR Ex-9 Mutation, and MPL W515, S505 Mutation, performed on bone marrow samples, serves as a molecular diagnostic test for suspected cases of myeloproliferative neoplasms (MPNs) including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF). The test initially detects the JAK2 V617F mutation, which is a common molecular marker in MPNs. If the JAK2 V617F mutation is detected, further mutation analysis for Jak2 Ex-12, MPL W515/S505, and CALR Ex-9 is not indicated, as the presence of the JAK2 V617F mutation confirms the diagnosis of an MPN. This comprehensive molecular testing approach provides valuable information for the diagnosis and classification of MPNs, aiding in the management and treatment decision-making for patients with suspected PV, ET, or PMF.
JAK2 V617 Mutation Test, With Reflex To Jak2 Ex- 12, CALR Ex-9 Mutation And MPL W515, S505 Mutation, Bone Marrow Price in Vizag
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the JAK2 V617 Mutation Test, With Reflex To Jak2 Ex- 12, CALR Ex-9 Mutation And MPL W515, S505 Mutation, Bone Marrow with a clear pricing structure
The price of JAK2 V617 Mutation Test, With Reflex To Jak2 Ex- 12, CALR Ex-9 Mutation And MPL W515, S505 Mutation, Bone Marrow in Vizag is ₹ 11,500
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test will assess for the JAK2V617F (exon 14) mutation first and will reflex to CALR mutation analysis, JAK2 exon mutation analysis and MPL mutation analysis when the JAK2V617F mutation is negative.
Your doctor may prescribe this test in conjunction with bone marrow histology and cytogenetic analysis to assist in the diagnosis of myeloproliferative neoplasms (MPN).
This reflex test sequentially evaluates for the common major gene variants associated with non-BCR-ABL1-positive myeloproliferative neoplasms until a variant is identified. The testing sequence is based on the reported frequency of gene variants in this disease group. Initial testing evaluates for the presence of the JAK2 V617F variant. If this result is negative or very low positive (0.06%-0.6%), testing proceeds with assessment for CALR gene variants. If the CALR result is also negative, then testing proceeds to evaluate for variants in exon 10 of the MPL gene. If either JAK2 V617F (>0.6%) or CALR variants are detected in the process, the testing algorithm ends; therefore, the complete reflex is followed only in the event of sequential negative variant. An integrated report is issued with the summary of test results.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.